Skip to main content
Fig. 1 | BMC Nephrology

Fig. 1

From: The clinical efficacy of fluticasone propionate combined with ACEI/ARB in the treatment of immunoglobulin A nephropathy

Fig. 1

The chart of experimental flow

A total of 142 patients who had completed the three-month break-in phase participated in the subsequent 9-month trial phase. Of these, 96 had a eGFR of at least 60 ml/min/1.73m2, and 46 had a eGFR of 45 to 59 ml/min/1.73m2. These patients were randomly assigned to continue support therapy or receive additional fluticasone

Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us